Treatment outcomes of patients with brca-mutated, recurrent ovarian cancer in University Hospital Center Split

Summary Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with plati -num-sensitive, Brca-mutated, recurrent ovarian cancer treated at the University Hospital center split in the period from June 2016 to april 2021. Methods: Data were collected retrospectively from a medical history of 28 patients with platinum-sensitive, Brca-mutated, recurrent ovarian cancer. Medical records were reviewed for clinico-pathological characteristics, number of previ ous chemotherapy lines and platinum-free interval before olaparib, response to olaparib, survival outcomes (time to disease progression, time from first cycle of olaparib to the first cycle of chemotherapy for the first and second relapse / progression, overall survival) and safety. Median follow up time was 27 months. Results: all patients were Brca mutated, with a 75% predominance of Brca1 mutation. the median platinum-free interval was 13 months. Most patients were treated after the first relapse (64%) with a three-weekly TC protocol (68%). olaparib maintenance therapy provided clinical control rate in 43% of cases. the median progression free survival was 24 months. Discontinuation of olaparib treatment was reported due to disease progression in 16 patients. the median time to first subsequent chemotherapy was 31 months and time to second subsequent chemotherapy was 38 months. The tolerabil ity of olaparib was good and the side effects were low intensity. The median overall survival is not reached. Conclusion: this retrospective analysis of patients with platinum-sensitive, Brca-mutated, recurrent ovarian cancer showed that the treatment outcomes, ie efficacy and tolerability of olaparib after platinum-based chemotherapy in everyday clinical practice, are comparable to those observed in clinical trials with olaparib in the same indications. ous lines of chemotherapy, ie number of previous relapses, response to chemotherapy and plati-num-free interval before olaparib. We analyzed efficacy of olaparib treatment. Disease response to treatment was monitored by the recist (re-sponse evaluation criteria in solid tumors) sys-tem. Response to therapy is defined as a complete response (cr) or complete disappearance of the tumor, partial response (partial response - pr), stable disease (stable Disease - sD) or progression of the disease (progressive Disease - pD). overall survival (OS) is defined by the period from dis ease diagnosis to death from a tumor or from some other cause. progression-free survival (pfs) is defined as the period from the diagnosis of ovarian, fallopian tube, and peritoneal cancer to disease progression, disease recurrence, and/or patient death. TFST (Time to First Subsequent Therapy) is defined as the period from the start of olaparib treatment to the start (chemo)therapy for the first relapse/progression. TSST (Time to Sec ond Subsequent Therapy) is defined as the period from the start of olaparib treatment to the start (chemo)therapy for second relapse/progression. We analyzed tolerability during olaparib treatment. The intensity of treatment side effects was assessed according to ctcae (common termi-nology criteria for advance events) criteria, v5.0. categorical variables were presented as per-centages, and a binomial or chi-square test was used to test their differences. Continuous vari ables were shown as median and interquartile range (IQR). We used Kaplan-Meier method to es timate the median progression free survival, time to first subsequent therapy, time to second subsequent therapy and overall survival with 95% confidence intervals (CI) in the population who last one olaparib. We per-formed statistical data